Boston Scientific Corporation
BSX Healthcare Medical Devices
Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 7.53%, EPS grew 14.8%, free cash flow grew 13.3% and total debt rose 8.95%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow BSX
Boston Scientific Corporation (BSX) EV/Sales
As of 16 October 2026, Boston Scientific Corporation (BSX) trades at a EV/Sales of 3.7×. Over the past ten years it has ranged from 2.9× (January 2015) to 9.9× (February 2025); the current reading is higher than 4% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.5× | (11.36%) |
| FY2024 | 8.5× | 30.63% |
| FY2023 | 6.5× | 11.32% |
| FY2022 | 5.8× | 2.43% |
| FY2021 | 5.7× | (3.43%) |
| FY2020 | 5.9× | (13.12%) |
| FY2019 | 6.8× | 19.43% |
| FY2018 | 5.7× | 28.09% |
| FY2017 | 4.4× | 6.12% |
| FY2016 | 4.2× | 3.69% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.6× | (28.49%) |
| Mar 2026 | 5.0× | (33.57%) |
| Dec 2025 | 7.5× | (6.31%) |
| Sep 2025 | 8.0× | (12.87%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PHG Koninklijke Philips N.V. compare | 1.4× |
| GEHC GE HealthCare Technologies Inc. compare | 1.9× |
| BSX Boston Scientific Corporation | 3.7× |
| MDT Medtronic PLC compare | 3.7× |
| STE STERIS plc compare | 3.8× |
| ABT Abbott Laboratories compare | 4.5× |
| SYK Stryker Corporation compare | 4.8× |
| DXCM DexCom, Inc. compare | 6.6× |
| EW Edwards Lifesciences Corporation compare | 7.2× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on BSX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement